Literature DB >> 18805465

Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice.

M A Hickey1, A Kosmalska, J Enayati, R Cohen, S Zeitlin, M S Levine, M-F Chesselet.   

Abstract

Huntington's disease is a neurodegenerative disorder, caused by an elongation of CAG repeats in the huntingtin gene. Mice with an insertion of an expanded polyglutamine repeat in the mouse huntingtin gene (knock-in mice) most closely model the disease because the mutation is expressed in the proper genomic and protein context. However, few knock-in mouse lines have been extensively characterized and available data suggest marked differences in the extent and time course of their behavioral and pathological phenotype. We have previously described behavioral anomalies in the open field as early as 1 month of age, followed by the appearance at 2 months of progressive huntingtin neuropathology, in a mouse carrying a portion of human exon 1 with approximately 140 CAG repeats inserted into the mouse huntingtin gene. Here we extend these observations by showing that early behavioral anomalies exist in a wide range of motor (climbing, vertical pole, rotarod, and running wheel performance) and non-motor functions (fear conditioning and anxiety) starting at 1-4 months of age, and are followed by progressive gliosis and decrease in dopamine and cyclic AMP-regulated phosphoprotein with molecular weight 32 kDa (DARPP32) (12 months) and a loss of striatal neurons at 2 years. At this age, mice also present striking spontaneous behavioral deficits in their home cage. The data show that this line of knock-in mice reproduces canonical characteristics of Huntington's disease, preceded by deficits which may correspond to the protracted pre-manifest phase of the disease in humans. Accordingly, they provide a useful model to elucidate early mechanisms of pathophysiology and the progression to overt neurodegeneration.

Entities:  

Mesh:

Year:  2008        PMID: 18805465      PMCID: PMC2665298          DOI: 10.1016/j.neuroscience.2008.08.041

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  77 in total

1.  Longitudinal evaluation of the Hdh(CAG)150 knock-in murine model of Huntington's disease.

Authors:  Mary Y Heng; Sara J Tallaksen-Greene; Peter J Detloff; Roger L Albin
Journal:  J Neurosci       Date:  2007-08-22       Impact factor: 6.167

2.  Mild prenatal stress in rats is associated with enhanced conditioned fear.

Authors:  W C Griffin; H D Skinner; A K Salm; D L Birkle
Journal:  Physiol Behav       Date:  2003-07

3.  Exploratory activity and fear conditioning abnormalities develop early in R6/2 Huntington's disease transgenic mice.

Authors:  Valerie J Bolivar; Kevin Manley; Anne Messer
Journal:  Behav Neurosci       Date:  2003-12       Impact factor: 1.912

4.  Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis.

Authors:  Laura Kennedy; Elizabeth Evans; Chiung-Mei Chen; Lyndsey Craven; Peter J Detloff; Margaret Ennis; Peggy F Shelbourne
Journal:  Hum Mol Genet       Date:  2003-10-21       Impact factor: 6.150

5.  Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats.

Authors:  Liliana B Menalled; Jessica D Sison; Ioannis Dragatsis; Scott Zeitlin; Marie-Françoise Chesselet
Journal:  J Comp Neurol       Date:  2003-10-06       Impact factor: 3.215

Review 6.  In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice.

Authors:  J F Cryan; C Mombereau
Journal:  Mol Psychiatry       Date:  2004-04       Impact factor: 15.992

7.  fMRI detection of early neural dysfunction in preclinical Huntington's disease.

Authors:  Janice L Zimbelman; Jane S Paulsen; Ania Mikos; Norman C Reynolds; Raymond G Hoffmann; Stephen M Rao
Journal:  J Int Neuropsychol Soc       Date:  2007-09       Impact factor: 2.892

8.  Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse.

Authors:  B Naver; C Stub; M Møller; K Fenger; A K Hansen; L Hasholt; S A Sørensen
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

Review 9.  The use of transgenic and knock-in mice to study Huntington's disease.

Authors:  M A Hickey; M-F Chesselet
Journal:  Cytogenet Genome Res       Date:  2003       Impact factor: 1.636

10.  Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.

Authors:  Alexandre Kuhn; Darlene R Goldstein; Angela Hodges; Andrew D Strand; Thierry Sengstag; Charles Kooperberg; Kristina Becanovic; Mahmoud A Pouladi; Kirupa Sathasivam; Jang-Ho J Cha; Anthony J Hannan; Michael R Hayden; Blair R Leavitt; Stephen B Dunnett; Robert J Ferrante; Roger Albin; Peggy Shelbourne; Mauro Delorenzi; Sarah J Augood; Richard L M Faull; James M Olson; Gillian P Bates; Lesley Jones; Ruth Luthi-Carter
Journal:  Hum Mol Genet       Date:  2007-05-21       Impact factor: 6.150

View more
  94 in total

1.  Mutant huntingtin-impaired degradation of beta-catenin causes neurotoxicity in Huntington's disease.

Authors:  Juliette D Godin; Ghislaine Poizat; Miriam A Hickey; Florence Maschat; Sandrine Humbert
Journal:  EMBO J       Date:  2010-06-08       Impact factor: 11.598

2.  A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.

Authors:  Damian M Cummings; Yasaman Alaghband; Miriam A Hickey; Prasad R Joshi; S Candice Hong; Chunni Zhu; Timothy K Ando; Véronique M André; Carlos Cepeda; Joseph B Watson; Michael S Levine
Journal:  J Neurophysiol       Date:  2011-11-09       Impact factor: 2.714

3.  Reduced expression of conditioned fear in the R6/2 mouse model of Huntington's disease is related to abnormal activity in prelimbic cortex.

Authors:  Adam G Walker; Jason R Ummel; George V Rebec
Journal:  Neurobiol Dis       Date:  2011-04-16       Impact factor: 5.996

4.  Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease.

Authors:  Miriam A Hickey; Chunni Zhu; Vera Medvedeva; Nicholas R Franich; Michael S Levine; Marie-Françoise Chesselet
Journal:  Mol Cell Neurosci       Date:  2011-10-20       Impact factor: 4.314

5.  The Huntington's disease mutation impairs Huntingtin's role in the transport of NF-κB from the synapse to the nucleus.

Authors:  Edoardo Marcora; Mary B Kennedy
Journal:  Hum Mol Genet       Date:  2010-08-25       Impact factor: 6.150

6.  Early autophagic response in a novel knock-in model of Huntington disease.

Authors:  Mary Y Heng; Duy K Duong; Roger L Albin; Sara J Tallaksen-Greene; Jesse M Hunter; Mathieu J Lesort; Alex Osmand; Henry L Paulson; Peter J Detloff
Journal:  Hum Mol Genet       Date:  2010-07-08       Impact factor: 6.150

7.  Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats.

Authors:  Aaron C Rising; Jia Xu; Aaron Carlson; Vincent V Napoli; Eileen M Denovan-Wright; Ronald J Mandel
Journal:  Exp Neurol       Date:  2010-12-28       Impact factor: 5.330

8.  Cortical Network Dynamics Is Altered in Mouse Models of Huntington's Disease.

Authors:  Elissa J Donzis; Ana María Estrada-Sánchez; Tim Indersmitten; Katerina Oikonomou; Conny H Tran; Catherine Wang; Shahrzad Latifi; Peyman Golshani; Carlos Cepeda; Michael S Levine
Journal:  Cereb Cortex       Date:  2020-04-14       Impact factor: 5.357

9.  A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.

Authors:  Danielle A Simmons; Nadia P Belichenko; Tao Yang; Christina Condon; Marie Monbureau; Mehrdad Shamloo; Deqiang Jing; Stephen M Massa; Frank M Longo
Journal:  J Neurosci       Date:  2013-11-27       Impact factor: 6.167

10.  Elevated NADPH oxidase activity contributes to oxidative stress and cell death in Huntington's disease.

Authors:  Antonio Valencia; Ellen Sapp; Jeffrey S Kimm; Hollis McClory; Patrick B Reeves; Jonathan Alexander; Kwadwo A Ansong; Nicholas Masso; Matthew P Frosch; Kimberly B Kegel; Xueyi Li; Marian DiFiglia
Journal:  Hum Mol Genet       Date:  2012-12-07       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.